Helen Cox

12 ta ish

Burnet Institute

1. Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures

   Helen Cox, Stobdan Kalon, Sholpan Allamuratova +6

   MaqolaOAOchiq kirish200713 iqtibos

   ABIABI:AkademIndex/2026.other.163905

2. Multidrug-resistant Tuberculosis in Central Asia

   Helen Cox, Juan Daniel Orozco, Roy Male +6

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyEmerging infectious diseases20049 iqtibos

   ABIABI:AkademIndex/2026.other.020023

3. Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

   Shama D. Ahuja, David Ashkin, Monika Avendano +70

   Sharh maqolaOAOchiq kirish20129 iqtibos

   ABIABI:AkademIndex/2026.other.027993

4. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

   Dennis Falzon, Neel R. Gandhi, Giovanni Battista Migliori +11

   Sharh maqolaOAOchiq kirish20124 iqtibos

   ABIABI:AkademIndex/2026.other.027990

5. Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis

   Mayara Lisboa Bastos, Hamidah Hussain, Karin Weyer +82

   Sharh maqolaOAOchiq kirish20144 iqtibos

   ABIABI:AkademIndex/2026.other.034193

6. The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia

   Helen Cox, Tanja Kubica, Daribay Doshetov +3

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyRespiratory Research20053 iqtibos

   ABIABI:AkademIndex/2005.article.000006

7. Emergence of Extensive Drug Resistance during Treatment for Multidrug-Resistant Tuberculosis

   Helen Cox, C Sibilia, Silke Feuerriegel +6

   BoshqaOAOchiq kirish20083 iqtibos

   ABIABI:AkademIndex/2026.other.175872

8. Recent controversies about <scp>MDR</scp> and <scp>XDR‐TB</scp>: <scp>G</scp>lobal implementation of the <scp>WHO</scp> shorter <scp>MDR‐TB</scp> regimen and bedaquiline for all with <scp>MDR‐TB</scp>?

   Keertan Dheda, Helen Cox, Aliasgar Esmail +3

   Sharh maqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.130259

9. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis

   Federica Fregonese, Shama D. Ahuja, Onno W. Akkerman +55

   Sharh maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.386597

10. Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance

    Helen Cox, Yared Kebede, Sholpan Allamuratova +8

    MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyPLoS Medicine20061 iqtibos

    ABIABI:AkademIndex/2006.article.000008

11. To treat or not to treat? Implementation of DOTS in Central Asia

    Helen Cox, Sally Hargreaves

    MaqolaTuberculosis Research and EpidemiologyThe Lancet20030 iqtibos

    ABIABI:AkademIndex/2003.article.000150

12. Tuberculosis ethambutol resistance: Concordance between phenotypic and genotypic test results

    Claudia Plinke, Helen Cox, Stobdan Kalon +3

    Maqola20090 iqtibos

    ABIABI:AkademIndex/2009.article.000604